These results indicate that the inhibition of PPARγ activity could be beneficial to prevent and treat obesity and obesity-related metabolic diseases, and it may even be superior to activation in terms of obesity based on fat formation and lipogenesis. The gene discussed is PPARG; the disease is Obesity.